A review in JAMA Otolaryngology–Head & Neck Surgery has pulled together what is known about GLP-1 drugs and obstructive sleep apnea, and its bottom line is a qualified one: the drugs work, and they work less well than CPAP. Across six meta-analyses the reduction in the apnea-hypopnea index ran from 5.7 to 21.9 events per hour. CPAP achieves about 31. If you are on a machine and hoping a drug will let you stop using it, this review does not support that.
What the evidence shows
Obstructive sleep apnea affects close to a billion adults worldwide, and obesity is present in 60% to 70% of cases, which is why a weight-loss drug was ever a plausible treatment. In December 2024 the FDA approved tirzepatide as the first medication indicated for moderate to severe obstructive sleep apnea in adults with obesity. The SURMOUNT-OSA phase 3 trials, on which that approval rested, reported reductions in the apnea-hypopnea index of 20 to 24 events per hour against placebo, with 42% to 50% of participants reaching disease remission, defined as an index below 5 events per hour or below 15 without symptoms.
The mechanism is mostly weight. The review describes reductions in tongue fat and in the parapharyngeal fat that contributes to upper airway collapse. It also flags preclinical work suggesting weight-independent routes, including GLP-1 receptor signalling at the carotid body affecting chemosensitivity, leptin pathway interactions bearing on upper airway neuromuscular control, and suppression of the NLRP3 inflammasome, while being clear that this is animal and laboratory evidence rather than clinical proof.
Where the drugs fit
The authors position GLP-1 drugs as complementary rather than substitutional: an adjunct alongside CPAP, a way to optimise someone before upper airway surgery, or potentially a way to widen the pool of candidates for a hypoglossal nerve stimulator. They name the patients most likely to benefit, being those with a body mass index above 30 who are either intolerant of CPAP or carrying obesity-related comorbidities, and the patients unlikely to benefit, being those without obesity and those whose obstruction is primarily anatomical.
That last point is the practically useful one and it is easy to miss. Sleep apnea driven by jaw or airway structure rather than by fat will not respond to weight loss, and no amount of drug changes the shape of an airway. CPAP adherence sits between 30% and 60%, which is the actual reason anyone is looking for alternatives at all. A drug that gets roughly two thirds of the way there in people who will take it may still beat a machine that people will not.
This is a narrative review rather than new data or a systematic synthesis, and it should be read as a specialty summarising its own position. Two gaps matter for anyone making a decision. Cardiovascular outcome benefit from treating sleep apnea with these drugs is unproven: the trials measured the apnea-hypopnea index, which is a marker, not the strokes and heart attacks that make untreated apnea dangerous. And the effect depends on continued treatment, since weight regain after stopping is common and nothing here suggests the airway improvement survives the weight returning. The authors also list unresolved technical questions, including how these drugs affect pharyngeal critical closing pressure and collapse patterns on drug-induced sleep endoscopy.
Sources: Harris A, Kaffenberger T. Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea: A Review. JAMA Otolaryngology–Head & Neck Surgery, published online 3 September 2026. doi:10.1001/jamaoto.2026.2266.
